Valuation: Daebongls.Co.,Ltd.

Market Cap 91.13B 64.25M 55.68M 52.04M 47.66M 89.58M 6.12B 91.04M 610M 239M 3.07B 241M 236M 10.26B P/E 2024
20.1x
P/E 2025 13.5x
Enterprise Value 103B 72.69M 63M 58.87M 53.92M 101M 6.93B 103M 690M 271M 3.47B 273M 267M 11.61B EV / Sales 2024
1.35x
EV / Sales 2025 1.38x
Free-Float
47.83%
Yield 2024
0.37%
Yield 2025 -
05-15 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-23 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-05 Daebongls.Co.,Ltd. announces Annual dividend, payable on April 24, 2026 CI
25-08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-21 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-05 Daebongls.Co.,Ltd. announced that it has received KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation ands another investor CI
24-09-03 Daebongls.Co.,Ltd. announced that it expects to receive KRW 30 billion in funding from Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd, Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., Lindeman Asia Investment Corporation and another investor CI
24-08-14 Daebongls.Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-16 Daebongls.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-20 Daebongls.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+1.48%
1 week+7.59%
Current month+7.59%
1 month+11.08%
3 months-23.18%
6 months-30.46%
Current year-29.44%
1 week 7,750
Extreme 7750
8,270
1 month 6,800
Extreme 6800
8,270
Current year 6,780
Extreme 6780
12,380
1 year 6,780
Extreme 6780
14,000
3 years 6,780
Extreme 6780
26,700
5 years 6,780
Extreme 6780
26,700
10 years 4,025
Extreme 4025
26,700
Manager TitleAgeSince
Chief Executive Officer 81 2013-03-26
Chief Executive Officer 55 2011-05-09
Comptroller/Controller/Auditor 68 2023-03-28
Director TitleAgeSince
Director/Board Member 55 2011-05-09
Director/Board Member 81 2013-03-26
Director/Board Member 58 2021-03-29
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+7.59%-39.60%-32.62% 63.71M
+3.90%+7.23%+96.91%+134.11% 1,057B
+0.99%+2.13%+51.05%+51.27% 625B
+0.78%-1.18%+25.21%+64.47% 435B
+1.58%+5.51%+51.42%+40.47% 363B
+0.65%+0.16%+34.81%+39.85% 296B
+0.79%-5.08%+9.78%+7.23% 249B
+1.52%+8.32%+44.75%+60.88% 222B
+0.34%-0.11%-5.23%-51.54% 209B
-0.11%+2.19%+11.43%+65.97% 165B
Average +1.19%+3.00%+28.05%+38.01% 362.08B
Weighted average by Cap. +1.78%+4.76%+51.76%+67.32%

Financials

2024 2025
Net sales 93.95B 66.24M 57.41M 53.65M 49.14M 92.36M 6.31B 93.86M 629M 247M 3.16B 249M 243M 10.58B 102B 71.95M 62.36M 58.28M 53.38M 100M 6.86B 102M 684M 268M 3.43B 270M 264M 11.49B
Net income 7.34B 5.17M 4.48M 4.19M 3.84M 7.21M 493M 7.33M 49.15M 19.28M 247M 19.43M 19.01M 826M 10.06B 7.09M 6.15M 5.74M 5.26M 9.89M 676M 10.05M 67.36M 26.42M 338M 26.64M 26.05M 1.13B
Net Debt -22.03B -15.53M -13.46M -12.58M -11.52M -21.66M -1.48B -22.01M -148M -57.88M -741M -58.35M -57.07M -2.48B 11.97B 8.44M 7.31M 6.84M 6.26M 11.77M 805M 11.96M 80.18M 31.45M 403M 31.7M 31.01M 1.35B
Logo Daebongls.Co.,Ltd.
DaebongLS Co Ltd is a Korea-based company primarily engaged in the manufacture of pharmaceutical and cosmetic ingredients. The Company operates its business through two segments. The Pharmaceutical Active Ingredient Business segment provides active pharmaceutical ingredients for respiratory treatments, hypertension treatments, and digestive system treatments. The Cosmetic Material Business segment manufactures and sells natural and functional cosmetic ingredients. In addition, the Company provides testing services for materials used on the skin and engages in real estate leasing business. The Company sells its products in domestic and overseas markets.
Employees
131
Date Price Change Volume
26-08-10 ₩8,220.00 +1.48% 16,335
26-08-07 ₩8,100.00 -0.49% 10,787
26-08-06 ₩8,140.00 0.00% 17,905
26-08-05 ₩8,140.00 +1.12% 11,656
26-08-04 ₩8,050.00 +3.87% 18,464
  1. Stock Market
  2. Stocks
  3. A078140 Stock